AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Encephalomyelitis - Pipeline Review, H2 2019 - ResearchAndMarkets.com

November 22, 2019

DUBLIN--(BUSINESS WIRE)--Nov 22, 2019--

The “Encephalomyelitis - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Report Scope

Reasons to Buy

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/np9hf7

View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005300/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/22/2019 09:31 AM/DISC: 11/22/2019 09:31 AM

http://www.businesswire.com/news/home/20191122005300/en